Despite difficulty in isolation and expansion, dendritic cells (DCs) have been used as immunotherapeutic agents in human cancer trials. Our search for viable alternatives to DCs focuses on B cells due to ease of isolation, activation, and their function as antigen presenting cells (APCs). While DCs are more effective at presenting antigen to naïve T cells, we hypothesized that multiple Bvac (B cell vaccine) injections would enhance their effectiveness. Therefore, the capacity of multiple Bvac injections to stimulate both primary and secondary CD8⁺ T cell responses was compared to those of single Bvac, and single DCvac treatments. Antigen-specific primary and secondary CD8⁺ T cell responses were determined by IFN-g production in response to antigen; also the protection against bacterial infection (Listeria monocytogenes) was quantified for the secondary response. In the primary and secondary responses the results show that the DCvac is still more effective at enhancing CD8⁺ T cells proliferation, however an increase in the Bvac efficacy was observed when comparing multiple treatments to single Bvac treatments. In the bacterial burden data we see that Bvacs were able to clear LM infection but not as effectively as the DCvac treatment. To identify potential factors that make DCvac more effective, in vitro CD8 proliferation by each vaccine was compared. This assay showed that B cells have the same ability as DCs to induce CD8⁺ T cell proliferation when the cells are fixed (no cytokine production). Future experiments will include more multiple BC vac treatments and in vitro comparisons of both Bvac and DCvac.